Asia Pacific Sarcopenia Treatment Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2024 –2030 |
 Taille du marché (année de référence) |
|
 Taille du marché (année de prévision) |
Dollars américains 861,882.42 |
 TCAC |
% |
| Principaux acteurs du marché |
Marché du traitement de la sarcopénie en Asie-Pacifique, par type de traitement (médicaments, vitamines/compléments alimentaires et autres), type (sarcopénie primaire et sarcopénie secondaire), stades (pré-sarcopénie, sarcopénie et sarcopénie sévère), voie d'administration (orale, injectable et autres), sexe (homme et femme), utilisateur final (hôpitaux, cliniques spécialisées, soins à domicile et autres), canal de distribution (appel d'offres direct, vente au détail et autres) - Tendances et prévisions de l'industrie jusqu'en 2030.
Analyse et taille du marché du traitement de la sarcopénie en Asie-Pacifique
Le principal facteur à l’origine de la croissance du marché du traitement de la sarcopénie en Asie-Pacifique est la prévalence croissante de la sarcopénie. En outre, la sensibilisation croissante à la sarcopénie et à ses effets néfastes sur la santé est un autre facteur clé de la croissance du marché. Des facteurs liés au mode de vie tels qu’une mauvaise alimentation et un comportement sédentaire influencent également le marché. Cependant, l’absence de diagnostic standardisé et le coût élevé du traitement et de l’intervention devraient freiner la croissance du marché.
Data Bridge Market Research estime que le marché du traitement de la sarcopénie en Asie-Pacifique devrait atteindre la valeur de 861 882,42 milliers USD d'ici 2030, à un TCAC de 5,9 % au cours de la période de prévision. Ce rapport de marché couvre également en profondeur l'analyse des prix et les avancées technologiques.
|
Rapport métrique |
Détails |
|
Période de prévision |
2023 à 2030 |
|
Année de base |
2022 |
|
Années historiques |
2021 (personnalisable de 2015 à 2020) |
|
Unités quantitatives |
Chiffre d'affaires en milliers de dollars américains, volumes en unités, prix en dollars américains |
|
Segments couverts |
Type de traitement (médicaments, vitamines/ compléments alimentaires et autres), type (sarcopénie primaire et sarcopénie secondaire), stades (pré-sarcopénie, sarcopénie et sarcopénie sévère), voie d'administration (orale, injectable et autres), sexe (homme et femme), utilisateur final (hôpitaux, cliniques spécialisées, soins à domicile et autres), canal de distribution (appel d'offres direct, vente au détail et autres) |
|
Pays couverts |
Japon, Australie, Inde, Chine, Corée du Sud, Nouvelle-Zélande, Singapour, Thaïlande, Malaisie, Vietnam, Taïwan, Indonésie, Philippines et reste de l'Asie-Pacifique |
|
Acteurs du marché couverts |
Abbott., Nestlé Health Science (une filiale de Nestlé SA), Novartis AG, Sanofi, Haleon Group of Companies., BASF SE, DSM, Fermenta Biotech Limited, AstaReal Co., Ltd., Metagenics, BioThrive Sciences., Wellona Pharma, The Vitamin Company India, Biogen SA, Healing Pharma India Pvt. Ltd. et entre autres |
Définition du marché
Sarcopenia treatment refers to the commercial landscape related to products and services aimed at preventing, managing, or addressing sarcopenia—a progressive age-related condition characterized by the loss of skeletal muscle mass, strength, and function, typically beginning around the age of 30 and accelerating after the age of 60. Sarcopenia has significant consequences on an individual's overall health and quality of life. There is a corresponding decline in muscle strength and endurance, making everyday tasks more challenging and increasing the risk of falls and fractures as muscle mass decreases. In addition, sarcopenia can lead to metabolic changes, insulin resistance, and an increased likelihood of obesity.
Asia-Pacific Sarcopenia Treatment Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Rising Prevalence of Sarcopenia
Sarcopenia is a medical condition characterized by the loss of muscle mass, strength, and function, particularly in older adults. They naturally experience a gradual loss of muscle mass and function, which predisposes them to sarcopenia as people age. The number of individuals at risk of developing sarcopenia is increasing steadily with the world's population aging. This demographic shift directly drives the demand for sarcopenia treatment options. The increasing prevalence of the condition means that more individuals require diagnosis and treatment, creating a larger patient pool for the sarcopenia treatment market.
People are living longer lives with advances in healthcare and medicine. However, as individuals age, they are more likely to develop sarcopenia. This longer life expectancy contributes to the overall prevalence of the condition. Chronic illnesses such as diabetes, cardiovascular disease, and cancer can lead to muscle loss and contribute to the development of sarcopenia. The increasing incidence of these conditions has a direct impact on the rising prevalence of sarcopenia.
- Growing Awareness of Sarcopenia and its Detrimental Effects on Health
The growing awareness of sarcopenia and its detrimental effects on health is a significant development in the field of healthcare and aging. There has been a significant increase in research and publications related to sarcopenia. Scientific studies, medical journals, and publications have provided healthcare professionals with valuable information about the condition's prevalence, diagnosis, and consequences. Medical schools and training programs have incorporated sarcopenia into their curricula. This ensures that healthcare professionals, including doctors, nurses, and physical therapists, receive education about sarcopenia, its risk factors, and management strategies.
Various advocacy groups and organizations have been actively promoting awareness about sarcopenia. These groups often collaborate with healthcare professionals to educate the public about the conditions risks and the importance of early diagnosis and intervention. Sarcopenia has received increased coverage in mainstream media, including articles, news reports, and documentaries. This exposure has helped raise awareness among the general public.
Opportunity
- Strategic Initiatives by Market Players
The sarcopenia treatment market is witnessing substantial growth as it is a progressive age-related condition characterized by the loss of muscle mass, strength, and function. It is a significant health concern, particularly among the elderly population, as it can lead to decreased mobility, increased risk of falls and fractures, and a decline in overall quality of life due to which key market players are proactively taking strategic initiatives for product development. Thus, opening up opportunities for market expansion and advancement.
Strategic initiative includes collaborations and partnerships with research institutions, healthcare organizations, and academic centers. Market players can leverage their knowledge and resources to accelerate the development and commercialization of sarcopenia treatments by collaborating with experts in the field. Such collaborations facilitate knowledge exchange, access to patient populations for clinical trials, and the pooling of expertise to drive innovation in the market.
Restraint / Challenge
- Lack of Standardized Diagnosis
Healthcare professionals may not routinely screen for the condition, especially in adults, which can hinder early intervention and treatment initiation. Without a standardized diagnosis, healthcare providers may use different criteria and methods to identify sarcopenia. This inconsistency can lead to variations in the reported prevalence of sarcopenia and the number of diagnosed cases, making it challenging to assess the true market size and demand for treatments.
Sarcopenia is a multifaceted condition that can affect individuals differently based on factors such as age, gender, and comorbidities. Patient groups may be heterogeneous, making it challenging to conduct clinical trials and research to evaluate treatment efficacy accurately without standardized diagnostic criteria. Clinical trials for sarcopenia treatments may use different diagnostic criteria, making it challenging to compare the results of various studies. This lack of standardization can hinder the development and approval of new treatments by regulatory agencies.
Recent Developments
- In September 2023, Biophytis received FDA (Food and Drug Administration) authorization to launch its SARA-31 study in the US, the first ever phase 3 study in sarcopenia. This will helps the organization in increases its product portfolio and brand image.
- In August 2023, Haleon, a Asia-Pacific leader in consumer health, and Direct Relief, announced that a humanitarian aid organization, has agreed to a multi-year commitment to expand access to everyday health for underserved communities while boosting emergency response and preparedness efforts around the world. This will increase the company’s brand image among others.
Asia-Pacific Sarcopenia Treatment Market Scope
The Asia-Pacific sarcopenia treatment market is segmented into seven notable segments based on treatment type, type, stages, route of administration, gender, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment Type
- Medications
- Vitamin/Dietary Supplements
- Others
On the basis of treatment type, the market is segmented into medications, vitamin/dietary supplements, and others.
Type
- Primary Sarcopenia
- Secondary Sarcopenia
On the basis of type, the market is segmented into primary sarcopenia and secondary sarcopenia.
Stages
- Pre-Sarcopenia
- Sarcopenia
- Severe Sarcopenia
On the basis of stages, the market is segmented into pre-sarcopenia, sarcopenia, and severe sarcopenia.
Route of Administration
- Oral
- Injectable
- Others
On the basis of route of administration, the market is segmented into oral, injectable, and others.
Gender
- Male
- Female
On the basis of gender, the market is segmented into male and female.
End User
- Hospitals
- Home Healthcare
- Specialty Clinics
- Others
On the basis of end user, the market is segmented into hospitals, home healthcare, specialty clinics, and others.
Distribution Channel
- Direct Tenders
- Retail Sales
- Others
On the basis of distribution channel, the market is segmented into direct tenders, retail sales, and others.
Asia-Pacific Sarcopenia Treatment Market Regional Analysis/Insights
The Asia-Pacific sarcopenia treatment market is segmented into seven notable segments based on treatment type, type, stages, route of administration, gender, end user, and distribution channel.
The countries covered in this market report are Japan, Australia, India, China, South Korea, New Zealand, Singapore, Thailand, Malaysia, Vietnam, Taiwan, Indonesia, Philippines, and Rest of Asia-Pacific.
Japan is expected to dominate Asia-Pacific as the strategic initiatives by the key market players are expanding significantly.
La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques, l'analyse des cinq forces du porteur et les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour chaque pays. En outre, la présence et la disponibilité des marques et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché du traitement de la sarcopénie en Asie-Pacifique
Le paysage concurrentiel du marché du traitement de la sarcopénie en Asie-Pacifique fournit des détails sur le concurrent. Les détails inclus sont un aperçu de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les nouvelles initiatives du marché, la présence en Amérique du Nord, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises par rapport au marché.
Certains des principaux acteurs du marché opérant sur le marché sont Abbott., Nestlé Health Science (une filiale de Nestlé SA), Novartis AG, Sanofi, Haleon Group of Companies., BASF SE, DSM, Fermenta Biotech Limited, AstaReal Co., Ltd., Metagenics, BioThrive Sciences., Wellona Pharma, The Vitamin Company India, Biogen SA, Healing Pharma India Pvt. Ltd. et entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA-PACIFIC SARCOPENIA TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 TREATMENT TYPE SEGMENT LIFELINE CURVE
2.8 MARKET END USER COVERAGE GRID
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL-
4.2 PORTER
5 REGULATIONS IN AUSTRALIA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF SARCOPENIA
6.1.2 GROWING AWARENESS OF SARCOPENIA AND ITS DETRIMENTAL EFFECTS ON HEALTH
6.1.3 LIFESTYLE FACTORS SUCH AS POOR NUTRITION AND SEDENTARY BEHAVIOUR
6.2 RESTRAINTS
6.2.1 LACK OF STANDARDIZED DIAGNOSIS
6.2.2 HIGH COST OF TREATMENT AND INTERVENTIONS
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS
6.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
6.4 CHALLENGES
6.4.1 COMPLICATIONS ASSOCIATED WITH THE SARCOPENIA TREATMENT
6.4.2 STRINGENT GOVERNMENT RULES AND REGULATION FOR PRODUCT APPROVAL
7 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE
7.1 OVERVIEW
7.2 VITAMIN/DIETARY SUPPLEMENTS
7.2.1 VITAMIN SUPPLEMENTS
7.2.2 PROTEIN SUPPLEMENTS
7.2.3 FATTY ACID SUPPLEMENTS
7.2.4 CREATINE
7.2.5 WHEY PROTEINS
7.2.6 L-CARNITINE
7.2.7 SOY
7.2.8 BETA-ALANINE
7.2.9 OSTARINE
7.2.10 COLLAGEN PEPTIDES
7.2.11 LIGANDROL
7.2.12 BRANCH-CHAIN AMINO ACIDS
7.2.13 HYDROXYMETHYLBUTYRATE (HMB)
7.2.14 MEDIUM CHAIN TRIGLYCERIDES
7.2.15 OTHERS
7.3 MEDICATIONS
7.3.1 OFF LABEL DRUGS
7.3.2 EMERGING DRUGS
7.3.2.1 ACE INHIBITORS
7.3.2.1.1 APPETITE STIMULANTS
7.3.2.1.2 ORAL ANTIDIABETIC DRUGS
7.3.2.1.3 OTHERS
7.4 OTHERS
8 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TYPE
8.1 OVERVIEW
8.2 PRIMARY SARCOPENIA
8.2.1 VITAMIN/DIETARY SUPPLEMENTS
8.2.2 MEDICATIONS
8.2.3 OTHERS
8.3 SECONDARY SARCOPENIA
8.3.1 VITAMIN/DIETARY SUPPLEMENTS
8.3.2 MEDICATIONS
8.3.3 OTHERS
9 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY STAGES
9.1 OVERVIEW
9.2 PRE-SARCOPENIA
9.3 SARCOPENIA
9.4 SEVERE SARCOPENIA
10 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
10.1 OVERVIEW
10.2 ORAL
10.3 INJECTABLES
10.4 OTHERS
11 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY GENDER
11.1 OVERVIEW
11.2 MALE
11.3 FEMALES
12 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.2.1 PUBLIC
12.2.2 PRIVATE
12.3 SPECIALTY CLINICS
12.4 HOME HEALTHCARE
12.5 OTHERS
13 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
13.3.1 HOSPITAL PHARMACIES
13.3.2 ONLINE PHARMACIES
13.3.3 OTHERS
13.4 OTHERS
14 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY COUNTRIES
14.1 ASIA-PACIFIC
14.1.1 JAPAN
14.1.2 CHINA
14.1.3 SOUTH KOREA
14.1.4 INDIA
14.1.5 AUSTRALIA
14.1.6 SINGAPORE
14.1.7 THAILAND
14.1.8 MALAYSIA
14.1.9 INDONESIA
14.1.10 PHILIPPINES
14.1.11 VIETNAM
14.1.12 NEW ZEALAND
14.1.13 TAIWAN
1.3.1. REST OF ASIA-PACIFIC
15 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, COMPANY
15.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
16 SWOT ANALYSIS
17 COMPANY PROFILES
17.1 ABBOTT
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 PRODUCT PORTFOLIO
17.1.4 RECENT DEVELOPMENT
17.2 NESTLÉ HEALTH SCIENCE (A SUBSIDIARY OF NESTLÉ S.A.)
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 PRODUCT PORTFOLIO
17.2.4 RECENT DEVELOPMENT
17.3 NOVARTIS AG
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 PRODUCT PORTFOLIO
17.3.4 PIPELINE PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 SANOFI
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 PRODUCT PORTFOLIO
17.4.4 RECENT DEVELOPMENT
17.5 HALEON GROUP OF COMPANIES.
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENT
17.6 ASTAREAL CO., LTD.
17.6.1 COMPANY SNAPSHOT
17.6.2 PRODUCT PORTFOLIO
17.6.3 RECENT DEVELOPMENT
17.7 BASF SE
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.8 DSM
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 FERMENTA BIOTECH LIMITED
17.9.1 COMPANY SNAPSHOT
17.9.2 REVENUE ANALYSIS
17.9.3 PRODUCT PORTFOLIO
17.9.4 RECENT DEVELOPMENT
17.1 HEALING PHARMA INDIA PVT.IND.
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.11 METAGENICS
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENT
17.12 THE VITAMIN COMPANY INDIA
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.13 WELLONA PHARMA
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENT
17.14 BIOPHYTIS
17.14.1 COMPANY SNAPSHOT
17.14.2 PIPELINE PORTFOLIO
17.14.3 RECENT DEVELOPMENT
17.15 IMMUNOFORGE INC.
17.15.1 COMPANY SNAPSHOT
17.15.2 PIPELINE PORTFOLIO
17.15.3 RECENT DEVELOPMENT
17.16 ONCOCROSS CO., LTD.
17.16.1 COMPANY SNAPSHOT
17.16.2 PIPELINE PORTFOLIO
17.16.3 RECENT DEVELOPMENT
17.17 OPKO HEALTH, INC.
17.17.1 COMPANY SNAPSHOT
17.17.2 REVENUE ANALYSIS
17.17.3 PIPELINE PORTFOLIO
17.17.4 RECENT DEVELOPMENT
17.18 REGENERON PHARMACEUTICALS INC.
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PIPELINE PORTFOLIO
17.18.4 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
Liste des tableaux
TABLE 1 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 2 ASIA-PACIFIC VITAMIN/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 3 ASIA-PACIFIC MEDICATINONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 4 ASIA-PACIFIC OFF-LABLE DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 5 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 6 ASIA-PACIFIC PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 7 ASIA-PACIFIC SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 8 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY STAGES , 2021-2030 (USD THOUSAND)
TABLE 9 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2021-2030 (USD THOUSAND)
TABLE 10 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY GENDER , 2021-2030 (USD THOUSAND)
TABLE 11 ASIA-PACIFIC HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 12 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL , 2021-2030 (USD THOUSAND)
TABLE 13 ASIA-PACIFIC RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL , 2021-2030 (USD THOUSAND)
TABLE 14 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 15 JAPAN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 16 JAPAN MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 17 JAPAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 18 JAPAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)
TABLE 19 JAPAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)
TABLE 20 JAPAN VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 21 JAPAN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 22 JAPAN PRIMARY SARCOPENIA IN SARCOPENIATREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 23 JAPAN SECONDARY SARCOPENIA IN SARCOPENIATREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 24 JAPAN SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 25 JAPAN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 26 JAPAN SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 27 JAPAN SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 28 JAPAN HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 29 JAPAN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 30 JAPAN RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 31 CHINA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 32 CHINA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 33 CHINA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 34 CHINA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)
TABLE 35 CHINA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)
TABLE 36 CHINA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 37 CHINA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 38 CHINA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 39 CHINA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 40 CHINA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 41 CHINA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 42 CHINA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 43 CHINA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 44 CHINA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 45 CHINA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 46 CHINA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 47 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 48 SOUTH KOREA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 49 SOUTH KOREA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 50 SOUTH KOREA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)
TABLE 51 SOUTH KOREA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)
TABLE 52 SOUTH KOREA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 53 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 54 SOUTH KOREA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 55 SOUTH KOREA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 56 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 57 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 58 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 59 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 60 SOUTH KOREA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 61 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 62 SOUTH KOREA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 63 INDIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 64 INDIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 65 INDIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 66 INDIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)
TABLE 67 INDIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)
TABLE 68 INDIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 69 INDIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 70 INDIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 71 INDIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 72 INDIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 73 INDIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 74 INDIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 75 INDIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 76 INDIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 77 INDIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 78 INDIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 79 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 80 AUSTRALIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 81 AUSTRALIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 82 AUSTRALIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)
TABLE 83 AUSTRALIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)
TABLE 84 AUSTRALIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 85 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 86 AUSTRALIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 87 AUSTRALIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 88 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 89 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 90 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 91 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 92 AUSTRALIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 93 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 94 AUSTRALIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 95 SINGAPORE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 96 SINGAPORE MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 97 SINGAPORE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 98 SINGAPORE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)
TABLE 99 SINGAPORE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)
TABLE 100 SINGAPORE VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 101 SINGAPORE SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 102 SINGAPORE PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 103 SINGAPORE SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 104 SINGAPORE SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 105 SINGAPORE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 106 SINGAPORE SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 107 SINGAPORE SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 108 SINGAPORE HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 109 SINGAPORE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 110 SINGAPORE RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 111 THAILAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 112 THAILAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 113 THAILAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 114 THAILAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)
TABLE 115 THAILAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)
TABLE 116 THAILAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 117 THAILAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 118 THAILAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 119 THAILAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 120 THAILAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 121 THAILAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 122 THAILAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 123 THAILAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 124 THAILAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 125 THAILAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 126 THAILAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 127 MALAYSIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 128 MALAYSIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 129 MALAYSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 130 MALAYSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)
TABLE 131 MALAYSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)
TABLE 132 MALAYSIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 133 MALAYSIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 134 MALAYSIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 135 MALAYSIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 136 MALAYSIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 137 MALAYSIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 138 MALAYSIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 139 MALAYSIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 140 MALAYSIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 141 MALAYSIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 142 MALAYSIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 143 INDONESIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 144 INDONESIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 145 INDONESIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 146 INDONESIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)
TABLE 147 INDONESIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)
TABLE 148 INDONESIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 149 INDONESIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 150 INDONESIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 151 INDONESIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 152 INDONESIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 153 INDONESIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 154 INDONESIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 155 INDONESIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 156 INDONESIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 157 INDONESIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 158 INDONESIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 159 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 160 PHILIPPINES MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 161 PHILIPPINES OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 162 PHILIPPINES OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)
TABLE 163 PHILIPPINES OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)
TABLE 164 PHILIPPINES VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 165 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 166 PHILIPPINES PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 167 PHILIPPINES SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 168 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 169 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 170 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 171 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 172 PHILIPPINES HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 173 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 174 PHILIPPINES RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 175 VIETNAM SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 176 VIETNAM MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 177 VIETNAM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 178 VIETNAM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)
TABLE 179 VIETNAM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)
TABLE 180 VIETNAM VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 181 VIETNAM SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 182 VIETNAM PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 183 VIETNAM SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 184 VIETNAM SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 185 VIETNAM SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 186 VIETNAM SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 187 VIETNAM SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 188 VIETNAM HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 189 VIETNAM SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 190 VIETNAM RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 191 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 192 NEW ZEALAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 193 NEW ZEALAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 194 NEW ZEALAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)
TABLE 195 NEW ZEALAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)
TABLE 196 NEW ZEALAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 197 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 198 NEW ZEALAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 199 NEW ZEALAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 200 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 201 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 202 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 203 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 204 NEW ZEALAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 205 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 206 NEW ZEALAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 207 TAIWAN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 208 TAIWAN MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 209 TAIWAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 210 TAIWAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)
TABLE 211 TAIWAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)
TABLE 212 TAIWAN VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 213 TAIWAN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 214 TAIWAN PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 215 TAIWAN SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 216 TAIWAN SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 217 TAIWAN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 218 TAIWAN SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 219 TAIWAN SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 220 TAIWAN HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 221 TAIWAN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 222 TAIWAN RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 223 REST OF ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
Liste des figures
FIGURE 1 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: MARKET END USERS COVERAGE GRID
FIGURE 8 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: SEGMENTATION
FIGURE 11 THE RISING PREVALENCE OF SARCOPENIA AND GROWING AWARENESS OF SARCOEPNIA AND ITS DETRIMENTAL EFFECT ON HEALTH ARE EXPECTED TO DRIVE THE GROWTH OF THE ASIA-PACIFIC SARCOPENIA TREATMENT MARKET FROM 2023 TO 2030
FIGURE 12 VITAMIN/DIETARY SUPPLEMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC SARCOPENIA MARKET IN 2023 AND 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA-PACIFIC SARCOPENIA TREATMENT MARKET
FIGURE 14 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, 2022
FIGURE 15 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 16 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2023-2030)
FIGURE 17 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 18 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY TYPE, 2022
FIGURE 19 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY TYPE, 2023-2030 (USD THOUSAND)
FIGURE 20 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 21 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 22 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY STAGES, 2022
FIGURE 23 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY STAGES, 2023-2030 (USD THOUSAND)
FIGURE 24 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY STAGES, CAGR (2023-2030)
FIGURE 25 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY STAGES, LIFELINE CURVE
FIGURE 26 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 27 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND)
FIGURE 28 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 29 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 30 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY GENDER, 2022
FIGURE 31 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY GENDER, 2023-2030 (USD THOUSAND)
FIGURE 32 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY GENDER, CAGR (2023-2030)
FIGURE 33 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY GENDER, LIFELINE CURVE
FIGURE 34 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY END USER, 2022
FIGURE 35 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 36 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY END USER, CAGR (2023-2030)
FIGURE 37 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 39 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)
FIGURE 40 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 41 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: SNAPSHOT (2022)
FIGURE 43 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
